US Patent 7964195 Ovr110 antibody compositions and methods of use
Patent 7964195 was granted and assigned to diaDexus, Inc. on June, 2011 by the United States Patent and Trademark Office.
All edits
The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
US Patent 07964195 Ovr110 antibody compositions and methods of use US Patent 7964195 Ovr110 antibody compositions and methods of use
US Patent 07964195 Ovr110 antibody compositions and methods of use
Find more entities like US Patent 7964195 Ovr110 antibody compositions and methods of use
